Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

711.68 +1.86 (+0.26%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Check Out What Whales Are Doing With LLY
 
Via Benzinga
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
If Nearly Half of S&P 500 Stocks Are Up in 2025, Then Why Is the Index Down 5%?
Via The Motley Fool
Topics Stocks
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns. 
Via The Motley Fool
The Vanguard S&P 500 ETF Is Sinking, but This Wall Street Analyst Predicts It Will Soar 168% by 2030
Via The Motley Fool
Topics ETFs Economy Stocks
Who Is Peter Thiel's Protégé, Michael Kratsios, Now Leading Trump's AI Strategy Amid Rising Tech Tensions With China
Michael Kratsios, former deputy to Peter Thiel, has been appointed to lead the U.S. government's AI strategy amid escalating competition with China, as tensions rise over China's DeepSeek AI model and... 
Via Benzinga
Topics Artificial Intelligence Government
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events. 
Via Benzinga
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing. 
Via Benzinga
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
1 Growth Stock With Major Catalysts on the Way to Buy and Hold
Via The Motley Fool
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reeling
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Microsoft Co-Founder Bill Gates Praises China As A Pioneer In Solar, Batteries, And AI: Warns Tensions Are Stifling Global Innovation
Bill Gates criticized escalating U.S.-China tensions for hindering global access to critical green technologies, praising China as a global leader in solar, batteries, and AI while warning that... 
Via Benzinga
Topics Artificial Intelligence
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
Eli Lilly shares demonstrated a power inflow at $821.70, after which LLY rose up to 1%, while S&P 500 dropped nearly 2% today. 
Via Benzinga
Topics Stocks
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. 
Via Benzinga
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500
Via The Motley Fool
Topics Stocks
Here's How Much $1000 Invested In Eli Lilly 20 Years Ago Would Be Worth Today
 
Via Benzinga
Why Novo Nordisk Stock Dipped on Thursday
Via The Motley Fool
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
1 Growth Stock Down 40% to Buy and Hold Forever
Via The Motley Fool
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. 
Via The Motley Fool
Organovo Provides Business Update
From Organovo, Inc.
Via GlobeNewswire
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Price Targets Show These 3 Stocks Near the $1 Trillion Mark
See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark. 
Via MarketBeat
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed. 
Via Benzinga
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
The "rapid" enrollment suggests there's still huge interest in the company's approach to obesity treatment. 
Via Investor's Business Daily
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
According to Direxion CEO Douglas Yones, Eli Lilly and Palo Alto Networks are prime candidates for leveraged trading. 
Via Benzinga
Topics ETFs
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.